UC given $1 million to develop skin cancer prevention treatment

November 03, 2006

A research team led by University of Cincinnati (UC) scientists has received $1 million from the National Cancer Institute to develop a new topical treatment that would not only increase skin pigmentation to block harmful ultraviolet (UV) rays, but also repair damage that can lead to skin cancer.

The researchers will work with a chemically modified hormone called alpha-melanocyte stimulating hormone (alpha-MSH). Known to increase skin pigmentation--the "tan" that reduces dangerous UV ray penetration--alpha-MSH has also been found to repair precancerous damage that UV rays do to skin cell DNA, the genetic material within cells.

"We hope to develop a new topical cream that will prevent skin cancer by both increasing skin pigmentation and at the same time repairing DNA damage caused by UV radiation," says study leader Zalfa Abdel-Malek, PhD, of UC's dermatology department.

"We have already shown that alpha-MSH repairs DNA damage caused by excessive sun exposure, thus reversing the cancer-causing effects of UV radiation," says Abdel-Malek, who has studied this phenomenon in isolated human melanocytes, the cells that produce the tanning pigment melanin.

Abdel-Malek will work with Ana Luisa Kadekaro, PhD, a UC dermatology instructor, to determine the ability of alpha-MSH, and synthesized versions of it, to reduce DNA damage in melanocytes that have been exposed to UV radiation in the lab.

To make it easier for the hormone to penetrate the fatty lipid layer of the skin, team members James Knittel, PhD, of UC's College of Pharmacy, and Carrie Haskell-Luevano, PhD, of the University of Florida, have already reduced alpha-MSH from its original peptide chain of 13 amino acids to a chain of only four amino acids. They hope to make the chain even smaller, and consequently more effective at penetrating the skin to target the melanocytes.

Dorothy Supp, PhD, of UC's department of surgery, will study the synthesized peptides on artificial skin to determine whether, if applied as a topical cream, they can be absorbed through the skin and delivered to the melanocytes.

Gerald Kasting, PhD, also of UC's College of Pharmacy, will test stability as well as penetration of the smaller peptides on live or cadaver skin.

According to the American Cancer Society, sun exposure is the main cause of skin cancer, of which 1 million new cases are diagnosed each year. Advanced melanoma, the deadliest form of skin cancer in the United States, resists chemotherapy and has a high potential for spreading to other organs.

Although melanoma currently accounts for only 8 percent of skin cancers, it causes almost all skin cancer deaths, and its incidence is rising at the rate of 4 percent a year. Melanoma is also the fifth and sixth most common cancer among men and women, respectively.

"The impact of this grant is potentially tremendous," says Abdel-Malek. "If this new prevention strategy works, it could ultimately reduce the ever-increasing incidence of skin cancer. It would especially benefit people with known high risk for skin cancer in general, especially those with fair skin, and might ultimately reduce the incidence of melanoma and prevent its recurrence in highly susceptible individuals."

University of Cincinnati

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.